
TOKYO -- Japan is set to host the world's first clinical trials involving the use of induced pluripotent stem (iPS) cells to treat heart failure.
iPS procedure raises hopes for alternative to donations and artificial organs
TOKYO -- Japan is set to host the world's first clinical trials involving the use of induced pluripotent stem (iPS) cells to treat heart failure.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.